InterMune, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report

Document Sample
InterMune, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report Powered By Docstoc
					InterMune, Inc.

_________________________________________________________________________________



InterMune, Inc.                                                               Financial Snapshot

                                                                              Operating Performance
Fast Facts
                                         3280 Bayshore Boulevard, Brisbane,   The company reported revenue of US$259.29 million
Headquarters Address
                                         94005,Other                          during the fiscal year 2010 (2010). The company's
                                                                              revenue grew at a CAGR of 30.00% during 2006–
Telephone                                + 1 415 4662200
                                                                              2010, with an annual growth of 432.43% over 2009. In
                                                                              2010, the company recorded an operating margin of
Fax                                      + 1 415 4662300                      49.63%, as against -229.69% in 2009.

Website                                  www.intermune.com
                                                                              Revenue and Margins
Ticker Symbol, Stock Exchange            ITMN, NASDAQ

Number of Employees                      122

Fiscal Year End                          December

Revenue (in US$ million)                 259.29




SWOT Analysis

Strengths                                Weaknesses                           Return on Equity

                                         Dependency on collaboration          The company recorded a return on equity (ROE) of
Strong financial performance
                                         agreements                           81.97% for the fiscal year 2010, as compared to its
Strong focus on research and                                                  peers, Actelion Ltd (Ticker: ATLN), Merck & Co., Inc.
                                         Lack of manufacturing facilities     (Ticker:   MRK)     and     Vertex   Pharmaceuticals
development activities
                                                                              Incorporated (Ticker: VRTX), which recorded ROEs of
Strong intellectual property portfolio                                        21.76%, 1.58% and            -149.74% respectively.
                                                                              Furthermore, the company reported an operating
                                                                              margin of 49.63% in 2010.
Opportunities                            Threats

Changing demographics                    Sovereign debt crisis                Return on Equity


Divesture of Danoprevir rights           Tightening regulations

Increasing healthcare expenditure        Uncertain R&D outcomes




                                                                              Liquidity Position

                                                                              The company reported a current ratio of 4.30 in 2010,
                                                                              as compared to its peers, Actelion Ltd, Merck & Co.,
                                                                              Inc. and Vertex Pharmaceuticals Incorporated, which
                                                                              recorded current ratios of 2.12, 1.86 and 2.23
                                                                              respectively. As of December 2010, the company
                                                                              recorded cash and short-term investments of worth
                                                                              US$295.07 million, against US$44.30 million current
                                                                              debt. The company reported a debt to equity ratio of
                                                                              0.87 in 2010 as compared to its peers, Actelion Ltd,
                                                                              Merck & Co., Inc. and Vertex Pharmaceuticals
                                                                              Incorporated, which recorded debt to equity ratios of
                                                                              0.25, 0.33 and 1.08 respectively.




___________________________________________________________________________________________

InterMune, Inc. - SWOT Profile                                                                                       Page 1
InterMune, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Net Debt vs. Gearing Ratio ..............................................................................................................................12
      2.2.4       Operational Efficiency ......................................................................................................................................13
      2.2.5       Solvency ..........................................................................................................................................................14
      2.2.6       Valuation ..........................................................................................................................................................15
    2.3       Competitive Benchmarking ..................................................................................................................................16
      2.3.1       Market Capitalization .......................................................................................................................................16
      2.3.2       Efficiency ..........................................................................................................................................................17
      2.3.3       Capital Expenditure ..........................................................................................................................................18
      2.3.4       Turnover – Inventory and Asset .......................................................................................................................19
      2.3.5       Liquidity ............................................................................................................................................................20
3     Mergers & Acquisitions and Partnerships ........................................................................................... 21
    3.1       M&A and Partnerships Strategy ...........................................................................................................................21
4     Recent Develo
				
DOCUMENT INFO
Description: ICD Research's "InterMune, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.